GRPH vs. OMGA, GNFT, IPHA, VCXB, VXRT, INMB, CGEN, OPT, ABOS, and DBVT
Should you be buying Graphite Bio stock or one of its competitors? The main competitors of Graphite Bio include Omega Therapeutics (OMGA), Genfit (GNFT), Innate Pharma (IPHA), 10X Capital Venture Acquisition Corp. III (VCXB), Vaxart (VXRT), INmune Bio (INMB), Compugen (CGEN), Opthea (OPT), Acumen Pharmaceuticals (ABOS), and DBV Technologies (DBVT). These companies are all part of the "biological products, except diagnostic" industry.
Graphite Bio (NASDAQ:GRPH) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment.
54.3% of Graphite Bio shares are held by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are held by institutional investors. 38.4% of Graphite Bio shares are held by insiders. Comparatively, 57.0% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Omega Therapeutics received 5 more outperform votes than Graphite Bio when rated by MarketBeat users. Likewise, 65.38% of users gave Omega Therapeutics an outperform vote while only 37.50% of users gave Graphite Bio an outperform vote.
Graphite Bio has a net margin of 0.00% compared to Omega Therapeutics' net margin of -3,802.89%. Graphite Bio's return on equity of -33.12% beat Omega Therapeutics' return on equity.
Omega Therapeutics has higher revenue and earnings than Graphite Bio. Omega Therapeutics is trading at a lower price-to-earnings ratio than Graphite Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Graphite Bio and Graphite Bio both had 2 articles in the media. Omega Therapeutics' average media sentiment score of 1.89 beat Graphite Bio's score of 0.26 indicating that Omega Therapeutics is being referred to more favorably in the news media.
Graphite Bio has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500.
Omega Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 228.77%. Given Omega Therapeutics' higher probable upside, analysts plainly believe Omega Therapeutics is more favorable than Graphite Bio.
Summary
Omega Therapeutics beats Graphite Bio on 11 of the 15 factors compared between the two stocks.
Get Graphite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Graphite Bio Competitors List
Related Companies and Tools